Asensus Surgical Inc
ASXC
AMX
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
0.41
USD
-0.02
(-4.33%)
Optionable: Yes Market Cap: 102 M 90-day average vol: 3,005,803
Previous close: 0.43 Open: 0.43 Bid: 0.4399 Ask: 0.4399
52 week range
0.35 3.75
Last updated: Thursday 19th May 2022
Valuation
Price per Sales TTM ($) | 14.09 |
Price per Book TTM ($) | 0.61 |
PE Ratio (TTM) | -1.40 |
Book Value per Share ($) | 0.64 |
5 Year PE Range-7.2 |
Returns
7 Day Return | 7.47% | |
1 Month Return | -17.21% | |
3 Month Return | -44.90% | |
1 Year Return | -75.57% | |
3 Year Return | -97.44% | |
5 Year Return | -93.99% | |
YTD Return | -62.94% |
Risk
Custom Beta One Year | 0.00 |
Custom Beta Three Years | 0.00 |
Beneish M Score | -180.66 |
Altman Z Score | -3.16 |
Financial Health
Technicals
RSI (14 Day) | 41.98 |
14 Day SMA ($) | 0.41 |
14 Day EMA ($) | 0.42 |
Money Flow Index | 81.86 |
Average True Range | 0.04 |
50 Day SMA ($) | 0.53 |
200 Day SMA ($) | 1.24 |
ADX | 15.10 |
MACD | -0.04 |
Growth
Free Cash Flow QoQ Growth | 49.91% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | -3.70% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -32.93 |
Profit Margin TTM (%) | -877.9 |
Return on Equity TTM (%) | -36.02 |
Return on Capital TTM (%) | -34.93 |
Interest Coverage Ratio | -112.50 |
Gross Margin TTM (%) | -35.9 |
Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2021
Yahoo Finance 2/28/2022
Asensus Surgical Q4 2021 Earnings Preview
Seeking Alpha 2/27/2022
Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2021 Financial and Operating Results Conference Call for February 28, 2022
Yahoo Finance 2/22/2022
Asensus Surgical: Reimagining the Future of Surgery
Yahoo Finance 1/26/2022
Asensus Surgical trades in green on prelim FY21 corporate update
Seeking Alpha 1/10/2022
Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update
Yahoo Finance 1/10/2022
Asensus Surgical to Participate in the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect 2022 Conference
Yahoo Finance 12/29/2021
Asensus Surgical Announces Purchase of Senhance Robotic System by RZD Medicine
Yahoo Finance 11/29/2021
Asensus Surgical Announces Franklin Medical Center to Initiate the Installation of the Senhance Surgical System
Yahoo Finance 11/15/2021
Asensus Surgical: Surgical Robot Company
Seeking Alpha 11/12/2021
Asensus Surgical, Inc. (ASXC) CEO Anthony Fernando on Q3 2021 Results - Earnings Call Transcript
Seeking Alpha 11/3/2021
Asensus Surgical up 4% after hours following strong Q3 2021 results
Seeking Alpha 11/3/2021
Asensus Surgical EPS in-line, beats on revenue
Seeking Alpha 11/3/2021
Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2021
Yahoo Finance 11/3/2021
Asensus Surgical Q3 2021 Earnings Preview
Seeking Alpha 11/2/2021
Asensus Surgical Announces Shinmatsudo Central General Hospital in Japan to Initiate Senhance Robotic Surgical System
Yahoo Finance 11/1/2021
Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 3, 2021
Yahoo Finance 10/20/2021
Asensus Surgical, Inc. Announces Hirosaki University Hospital to Initiate Senhance Robotic Surgery Program
Yahoo Finance 10/6/2021
Asensus Surgical board chair Paul LaViolette stepping down
Seeking Alpha 10/4/2021
Asensus Surgical Announces Board Chair Transition
Yahoo Finance 10/4/2021
| NA |
|---|
| could not broadcast input array from shape (20) into shape (0) |
|---|
ASXC Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 M | 1 M | 401000 | 0 | 2 M | 7 M | 24 M | 9 M | 3 M |
| Cost of sales | 3 M | 2 M | -1 M | -3 M | -8 M | -6 M | 814000 | 6 M | -11 M |
| Gross operating profit | -2 M | -2 M | 113000 | 0 | 450000 | 3 M | 10 M | -10 M | 907000 |
| Selling Gen & administrative expense | 6 M | 6 M | 7 M | 11 M | 20 M | 30 M | 40 M | 47 M | 27 M |
| Research & development expense | 6 M | 13 M | 28 M | 30 M | 29 M | 22 M | 22 M | 22 M | 17 M |
| Operating income | -15 M | -22 M | -37 M | -43 M | -56 M | -59 M | -64 M | -92 M | -57 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -7000 | -5 M | 0 | -4 M | -68 M | -86 M | 2 M | -62 M | -4 M |
| Pre-tax Income (EBT) | -15 M | -28 M | -38 M | -48 M | -126 M | -148 M | -65 M | -157 M | -61 M |
| Income taxes | 0 | 0 | 0 | -1 M | -6 M | -3 M | -3 M | -3 M | -2 M |
| Net income from total operations | -15 M | -28 M | -38 M | -47 M | -120 M | -145 M | -62 M | -154 M | -59 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -15 M | -28 M | -38 M | -47 M | -120 M | -145 M | -62 M | -154 M | -59 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 711000 |
| Net income available for common | -15 M | -28 M | -38 M | -47 M | -120 M | -145 M | -62 M | -154 M | -60 M |
| Depreciation | 2 M | 1 M | 1 M | 3 M | 9 M | 10 M | 13 M | 12 M | 14 M |
| Amortization | 0 | 500000 | 503000 | 2 M | 7 M | 8 M | 11 M | 10 M | 11 M |
| Operating income before depreciation (EBITDA) | -13 M | -21 M | -35 M | -39 M | -115 M | -135 M | -48 M | -140 M | -47 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -9.75 | -29.25 | -8.32 | -7.67 | -13.91 | -12.61 | -3.88 | -8.69 | -0.85 |
| Diluted EPS total | -9.75 | -29.25 | -8.32 | -7.67 | -13.91 | -12.61 | -3.88 | -8.69 | -0.85 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!